Merck Boosts Immuno-oncology with Viralytics Buy

22.02.2018 - US drugmakerMerck & Co. has agreed to buy Australia’s Viralytics for $394 million, in a deal that will boost its immuno-oncology portfolio. Through the acquisition, which will see...